uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide…
12 analysts rate QURE Buy on consensus.
Consensus price target: $60.16 (+142.29% upside from $24.83)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Kaye Jack director | Jun 30, 2026 | Sale | 4,107 | $190.93K |
| Abi-Saab Walid Chief Medical Officer | Jun 30, 2026 | Sale | 10,000 | $464.6K |
| Abi-Saab Walid Chief Medical Officer | Jun 30, 2026 | Sale | 20,000 | $928K |
| Kaye Jack director | Jun 30, 2026 | Sale | 17,060 | $792.1K |
| Kapusta Matthew C director, CEO, Managing Director | Jun 25, 2026 | Sale | 28,716 | $1.44M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $16.1M | -40.64% | $-198.97M |
| 2024 | $27.12M | +71.17% | $-239.56M |
| 2023 | $15.84M | -85.12% | $-308.48M |
Stock data for QURE: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics